66622-47-7Relevant articles and documents
Preparation method of ibuprofen impurity A
-
Paragraph 0040-0041, (2018/12/02)
The invention discloses a preparation method of an ibuprofen impurity A (shown as a formula I). According to the preparation method, 3-methyl bromophenylacetate is used as a raw material and methyl onhydrogen is removed through alkali; then Suzuki reaction is carried out and the raw material is coupled with isobutaneboronic acid to generate 2-(3-isobutyl phenyl)methyl propionate; finally, the 2-(3-isobutyl phenyl)methyl propionate is hydrolyzed and neutralized to obtain the ibuprofen impurity A. The preparation method disclosed by the invention has the advantages that the raw material is cheap and easy to obtain, synthesis steps are simple, reaction conditions are moderate and the post-treatment is simple; a technology is stable and has good repeatability, so that the production cost isgreatly reduced, and commercial production and batch supply are facilitated.
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors
Allegretti, Marcello,Bertini, Riccardo,Cesta, Maria Candida,Bizzarri, Cinzia,Di Bitondo, Rosa,Di Cioccio, Vito,Galliera, Emanuela,Berdini, Valerio,Topai, Alessandra,Zampella, Giuseppe,Russo, Vincenzo,Di Bello, Nicoletta,Nano, Giuseppe,Nicolini, Luca,Locati, Massimo,Fantucci, Piercarlo,Florio, Saverio,Colotta, Francesco
, p. 4312 - 4331 (2007/10/03)
The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCLS-induced human PMNs chemotaxis. We report here molecular modeling studies showing a putative interaction site of 1 in the TM region of CXCR1. The binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling experiments. The molecular model driven medicinal chemistry optimization of 1 led to a new class of potent and specific inhibitors of CXCL8 biological activity. Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury.